Metagenics UltraInflamX Plus 360 provides specialized support including reduced iso-alpha acids, L-glutamine and easily digestible rice protein. Supports the digestive tract against the effects of inflammation.
- Features selective kinase response modulators (SKRMs) in the form of RIAA, which has been shown to beneficially support the function of enzymes involved in inflammatory processes.
- RIAA has demonstrated potent antioxidant activity and research suggests that it may help improve overall redox status through influencing inflammation signaling molecules such as NF-KB, COX-2, and PGE2
- Includes ginger and rosemary, which may help support healthy eicosanoid and cytokine metabolism
- Provides turmeric extract, which has been shown in research to inhibit the activities of a wide variety of enzymes, cytokines, eicosanoids, and reactive species implicated in pain and inflammation
- Supplies a low-allergenic potential protein base in the form of rice protein concentrate
Revolutionary New Improvements to the UltraInflamX Plus 360°
- Strategic macro- and micronutrient profiles to deliver targeted nutritional support for patients with IBD
- Proprietary vegan pea/rice protein blend
- Added essential amino acids, including branched chain amino acids
- Bioavailable curcumin
- Selective kinase response modulators (SKRMs) as bioavailable xanthohumol (XNT)
- Beneficial prebiotic fiber, in the form of isomalto-oligosaccharides (IMO)1
- Improved taste & texture—preferred in consumer testing
- Lower sugar content than the original formulas; Original Spice flavor reformulation has 4 grams of sugar per serving compared to 9 grams in the previous formula (~56% less)
- Each serving provides 400 mg alpha-linolenic acid (an omega-3 fatty acid) from flaxseed
- Still non-GMO and free of dairy, gluten, and soy
Note: This product contains plant pigments that will stain clothing and surfaces. This product is non-GMO, dairy free, and gluten free. Keep tightly closed in a cool, dry place.
Caution: This product is to be used under the direct supervision of a physician or other licensed healthcare practitioner. Do not engage in any diet supplying less than 800 calories per day without medical supervision. Excess vitamin A intake may be toxic and may increase the risk of birth defects. Pregnant women and women who may become pregnant should not exceed 5000 IU of preformed vitamin A (retinyl palmitate) per day.
- Do not use if pregnant or nursing or if taking anticoagulants
- If taking medication, consult your physician before taking this product
- Keep out of reach of children
- Do not exceed recommended dose
* These statements have not been evaluated by the Food and Drug Administration. This Product is not intended to diagnose, treat, cure or prevent any disease.
1. Massironi S, Rossi RE, Cavalcoli FA, Della Valle S, Fraquelli M, Conte D. Nutritional deficiencies in inflammatory bowel disease : therapeutic approaches. Clin Nutr. Dec 2013;32(6):904-910.
2. Hartman C, Eliakim R, Shamir R. Nutritional status and nutritional therapy in inflammatory bowel diseases. World J Gastroenterol. 2009;15(21):2570-2578.
3. Volpi E, Kobayashi H, Sheffield-Moore M, Mittendorfer B, Wolfe RR. Essential amino acids are primarily responsible for the amino acid stimulation of muscle protein anabolism in healthy elderly adults. Am J Clin Nutr. 2003;78(2):250-258.
4. Katsanos CS, Kobayashi H, Sheffield-Moore M, Aarsland A, Wolfe RR. A high proportion of leucine is required for optimal stimulation of the rate of muscle protein synthesis by essential amino acids in the elderly. Am J Physiol Endocrinol Metab. 2006;291(2):E381-387.
5. Sugawara T, Ito Y, Nishizawa N, Nagasawa T. Supplementation with dietary leucine to a protein-deficient diet suppresses myofibrillar protein degradation in rats. J Nutr Sci Vitaminol (Tokyo). 2007;53(6):552-555.
6. Ishikawa T. Early administration of branched-chain amino acid granules. World J Gastroenterol. 2012;18(33):4486-4490.
7. Miller AL. Therapeutic considerations of L-glutamine: a review of the literature. Altern Med Rev. 1999;4(4):239-248.
8. Neu J, DeMarco V, Li N. Glutamine: clinical applications and mechanisms of action. Curr Opin Clin Nutr Metab Care. 2002;5(1):69-75.
9. Sido B, Seel C, Hochlehnert A, Breitkreutz R, Droge W. Low intestinal glutamine level and low glutaminase activity in Crohn’s disease: a rationale for glutamine supplementation? Dig Dis Sci. 2006;51(12):2170-2179.
10. Coeffier M, Marion-Letellier R, Dechelotte P. Potential for amino acids supplementation during inflammatory bowel diseases. Inflamm Bowel Dis. 2010;16(3):518-524.
11. Massironi S, Rossi RE, Cavalcoli FA, Della Valle S, Fraquelli M, Conte D. Nutritional deficiencies in inflammatory bowel disease: therapeutic approaches. Clin Nutr. 2013;32(6):904-910.
12. Unpublished data. AKAY research in collaboration with Amala Cancer Research Institute in India and SMO connect clinical research services Pvt Ltd, India.
13. Vernazza CL, Gibson GR, Rastell RA. Carbohydrate preference, acid tolerance and bile tolerance in five strains of Bifidobacterium . J Appl Microbiol. 2006;100:846-853.
14. Ribnicky DM, Roopchand DE, Poulev A, et al. Artemisia dracunculus L. polyphenols complexed to soy protein show enhanced bioavailability and hypoglycemic activity in C57BL/6 mice. Nutrition. 2014;30:S4-10.
15. Yousef GG, Grace MH, Medina JL, et al. Concentrating immunoprotective phytoactive compounds from fruits and vegetables into shelf-stable protein-rich ingredients. Plant Foods Hum Nutr. 2014;69:317-324.
16. Guzman I, Grace MH, Yousef GG, Raskin I, Lila MA. Novel strategies for capturing health-protective mango phytochemicals in shelf stable food matrices. Int J Food Sci Nutr. 2015;66:175-185.
17. Plazar J, Zegura B, Lah TT, Filipic M. Protective effects of xanthohumol against the genotoxicity of benzo(a)pyrene (BaP), 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) and tert-butyl hydroperoxide (t-BOOH) in HepG2 human hepatoma cells. Mutat Res. 2007;632:1-8. 18. Plazar J, Filipic M, Groothuis GM. Antigenotoxic effect of Xanthohumol in rat liver slices. Toxicol In Vitro. 2008;22:318-327.
19. Dorn C, Heilmann J, Hellerbrand C. Protective effect of xanthohumol on toxin -induced liver inflammation and fibrosis. Int J Clin Exp Pathol. 2012;5:29-36.
20. Pinto C, Duque AL, Rodriguez-Galdon B, Cestero JJ, Macias P. Xanthohumol prevents carbon tetrachloride-induced acute liver injury in rats. Food Chem Toxicol. 2012;50:3405-3412.
21. Rodriguez RJ, Miranda CL, Stevens JF, Deinzer ML, Buhler DR. Influence of prenylated and non-prenylated flavonoids on liver microsomal lipid peroxidation and oxidative injury in rat hepatocytes. Food Chem Toxicol. 2001;39:437.
22. Lee YM, Hsieh KH, Lu WJ, et al. Xanthohumol, a prenylated flavonoid from hops (Humulus lupulus), prevents platelet activation in human platelets. Evid Based Complement Alternat Med. 2012;2012:852362.
23. Harikumar KB, Kunnumakkara AB, Ahn KS, et al. Modification of the cysteine residues in IkappaBalpha kinase and NF-kappaB (p65) by xanthohumol leads to suppression of NF-kappaB-regulated gene products and potentiation of apoptosis in leukemia cells. Blood. 2009;113:2003-2013.
24. Albini A, Dell’Eva R, Vene R, et al. Mechanisms of the antiangiogenic activity by the hop flavonoid xanthohumol: NF-kappaB and Akt as targets. Faseb J. 2006;20:527-529.
25. Vecchi Brumatti L, Marcuzzi A, Tricarico PM, Zanin V, Giradelli M, Bianco AM. Curcumin and inflammatory bowel disease: potential and limits of innovative treatments. Molecules. 2014;19(12):21127-21153.
There are no reviews yet.